Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713381 | 0.90 | GPR119 (0.72) | GPR119CYP2C9KCNH2 | |
| SCHEMBL3244959 | 0.86 | GPR119 (0.59) | GPR119CYP2C9KCNH2 | |
| SCHEMBL2372630 | 0.82 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1071583 | 0.81 | GPR119 (0.69) | GPR119CYP2C9KCNH2 | |
| SCHEMBL13633398 | 0.81 | GPR119 (0.71) | GPR119CYP2C9KCNH2 | |
| SCHEMBL5817927 | 0.78 | GPR119 (0.56) | GPR119CYP2C9KCNH2 | |
| SCHEMBL4355645 | 0.77 | CYP2C9 (0.46) | GPR119CYP2C9 | |
| SCHEMBL391428 | 0.76 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1071669 | 0.75 | GPR119 (0.58) | GPR119CYP2C9KCNH2 | |
| SCHEMBL5133272 | 0.75 | GPR119 (0.60) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-2051976-B1 | 4-[5-METHOXY-6-(2-METHYL-6-[1,2,4]TRIAZOL-1-YL-PYRIDIN-3-YLAMINO)-PYRIMIDIN-4-YLOXY]-PIPERIDINE-1-CARBOXYLC ACID ISOPROPYL ESTER AS MODULATOR OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2010-05-26 | — | — | EP | disclosed |